Patents by Inventor Seema Kantak

Seema Kantak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTISPECIFIC BINDING AGENTS AND USES THEREOF
    Publication number: 20240010751
    Abstract: The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding domain that binds to CD47, including human CD47, and one or more additional binding domains that bind to one or more targets that are not CD47, such as PD-L1 and uses thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: January 11, 2024
    Applicant: EXELIXIS, INC.
    Inventors: Bryan GLASER, Bonnie HAMMER, Seema KANTAK
  • CD47 BINDING AGENTS AND USES THEREOF
    Publication number: 20230357391
    Abstract: The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: November 9, 2023
    Applicant: EXELIXIS, INC.
    Inventors: Bryan GLASER, Bonnie HAMMER, Seema KANTAK
  • PD-L1 BINDING AGENTS AND USES THEREOF
    Publication number: 20230303699
    Abstract: The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and uses thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: September 28, 2023
    Applicant: EXELIXIS, INC.
    Inventors: Bryan GLASER, Bonnie HAMMER, Seema KANTAK
  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20200368321
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Il-2R?-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
    Patent number: 10786552
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 29, 2020
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20180344810
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2R?-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
    Patent number: 10010587
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: July 3, 2018
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
    Publication number: 20170128539
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: February 20, 2015
    Publication date: May 11, 2017
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • VE-CADHERIN BINDING BIOCONJUGATE
    Publication number: 20170112941
    Abstract: This disclosure provides bioconjugate comprising a glycan and at least one peptide comprising a VE-Cadherin binding unit conjugated thereto, compositions comprising the same, and methods of use thereof.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 27, 2017
    Inventors: Alyssa Panitch, John Eric Paderi, Katherine Allison Stuart, Seema Kantak, Nathan Bachtell
  • Fully human anti-VEGF antibodies and methods of using
    Patent number: 8216571
    Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 10, 2012
    Assignee: Schering Corporation
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang, Toshihiko Takeuchi, Seema Kantak, Chin-Yi Huang
  • FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
    Publication number: 20110097340
    Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 28, 2011
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang, Toshihiko Takeuchi, Seema Kantak, Chin-Yi Huang's
  • USES OF ANTI-CD40 ANTIBODIES
    Publication number: 20110002934
    Abstract: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.
    Type: Application
    Filed: November 7, 2008
    Publication date: January 6, 2011
    Inventors: Mohammad Luqman, Sherna Budhabhatti, Yongyu Wang, Seema Kantak, Ssucheng J. Hsu, Amer M. Mirza